Gout is a common and chronic disease, affecting more than 8 million individuals in the United States; its prevalence has increased in recent decades and will continue to increase as the population ages. It is now known that hyperuricemia can not only precipitate gout but also lead to a host of serious health consequences if left undiagnosed, untreated, or undertreated. Thus, evidence-based recommendations advise that, for chronic gout, serum urate levels should be lowered with the use of both pharmacologic and nonpharmacologic measures and maintained below a specific target, which should be individualized for each patient. As understanding of the pathophysiology of hyperuricemia and gout has increased, more precisely targeted therapeutic approaches have emerged and promise to improve outcomes and QoL, especially in patients with gout that is considered refractory to traditional therapies.
This article will provide learners with an overview of the current state of gout management, inclusive of diagnosis and treatment. The e-article will encourage learners to reflect on their own practice relative to how they manage the care of patients with gout and to identify areas in which they require education to improve their knowledge, competence, practice, and, by extension, health outcomes for their patients.